RSS

Novartis

Oliver Leatham, vice president and global head of value and access at Certara, writes about the complex issues that surrounds assigning a value to new drugs. Read more

Opinion

EPM editor Reece Armstrong examines the consequences of faulty data for a well-known pharma company. Read more

Opinion

Pharma company Novartis UK has launched a new digital campaign to help people living with migraines be less fearful of their condition. Read more

News

Biotechnology company Lonza has announced it is to purchase a sterile drug product fill & finish facility from major pharma player Novartis. Read more

News

European Pharmaceutical Manufacturer editor Reece Armstrong examines both sides of the argument relating to the world's most expensive drug. Read more

Opinion

Three health start-ups have been selected to join a new acceleration programme launched by pharma company Novartis and 02’s innovation arm, Wayra UK. Read more

News

Swiss drugmaker Novartis has announced a five-year partnership with the University of Oxford’s Big Data Institute (BDI) to study how artificial intelligence (AI) can provide insights into complex diseases. Read more

News

A collaboration between a Canadian supplier of medical cannabis and a biopharma is being touted as a major step towards bringing medical cannabis to patients across the globe. Read more

News

Healthcare group Novartis will cut 2,000 jobs around the world in response to a changing product portfolio, the company has announced. Read more

News

Novartis’ generics and biosimilars division, Sandoz, has launched the second edition of its Healthcare Access Challenge (Hack), the company has announced. Read more

News

Healthcare solutions provider, Novartis, has announced that the European Commission has approved its combination therapy, Tafinlar + Mekinist, for adjuvant treatment of stage III patients with BRAF V600 mutation-positive melanoma. Read more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

Healthcare solutions provider, Novartis, has announced new data demonstrating that its twice-a-day medicine, Entresto (sacubitril/valsartan) can be initiated early and safely in hospitalised patients after an acute heart failure episode. Read more

News

A brief round up of some of the latest developments in the industry, including a review into medical marijuana and a potential win for Trump in drug pricing… Read more

Opinion

The European Commission (EC) has approved Novartis’ Aimovig (erenumab) for the prevention of migraine in adults experiencing four or more migraines per month. Read more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

In this case study, a prediction model is used in conjunction with an examination of a tablet profile to resolve sticking issues. Read more

Opinion

The US FDA has accepted Novartis’ supplemental new drug application (sNDA) and granted priority review designation to Promacta (eltrombopag) in combination with standard immunosuppressive therapy (IST) for first-line treatment of SAA Read more

News

The group general counsel of Swiss pharma company, Novartis, has stepped down from his role, taking personal responsibility for what he has described as the ‘erroneous’ agreement made with Essential Consultants, which is owned by Michael Cohen Read more

News

A treatment for relapsing multiple sclerosis (Gilenya — fingolimod) has been approved for use in children and adolescents aged 10 years and older by the US Food and Drug Administration (FDA). Read more

News